Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Endocrinology

FDA Approves Oral Testosterone Replacement Therapy Tlando

Brian Park, PharmD

April 7, 2022

The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.

Type 2 Diabetes

Ozempic 2 mg Dose Approved to Provide Additional Glycemic Control in Type 2 Diabetes

Brian Park, PharmD

April 7, 2022

The approval was based on data from the phase 3b SUSTAIN FORTE trial, which compared Ozempic 2 mg to 1 mg in adults with type 2 diabetes.

Thyroid

Hypoparathyroidism Effectively Managed With TransCon PTH in Phase 3 Trial

Brian Park, PharmD

March 21, 2022

The phase 3 PaTHway trial included 82 adults with chronic hypoparathyroidism.

Hypertension

Once-Daily Extended-Release Clonidine Available for Hypertension Treatment

Brian Park, PharmD

March 7, 2022

The Company acquired exclusive rights to commercialize the product from Tris Pharma in February 2021.

General Endocrinology

Clinical Benefit Seen With In-Hospital Initiation of Empagliflozin in Heart Failure Patients

Brian Park, PharmD

March 3, 2022

Findings showed that patients treated with empagliflozin were 36% more likely to experience a clinical benefit.

National Cancer Institute investigators studied the mechanisms of exceptional responses in a large cohort of patients with solid tumors.

Cardiovascular and Metabolic Disorders

Generic Version of Cystadane Now Available

Brian Park, PharmD

February 17, 2022

Betaine Anhydrous Powder is a methylating agent indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations.

General Medicine

FDA Authorizes Bebtelovimab for Mild to Moderate COVID-19 Treatment

Brian Park, PharmD

February 15, 2022

The EUA was supported by data from the phase 2 BLAZE-4 trial which evaluated bebtelovimab in nonhospitalized patients with mild to moderate COVID-19.

Diabetes

Vabysmo Approved for Wet AMD, Diabetic Macular Edema

Brian Park, PharmD

February 1, 2022

Vabysmo is a humanized bispecific antibody that works by inhibiting the angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) pathways.

Diabetes

FDA Clears Omnipod 5 Tubeless Insulin System for Diabetes Management

Brian Park, PharmD

February 1, 2022

The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System.

Diabetes

Insulin Prefilled Pens Recalled Due to Missing Label

Brian Park, PharmD

January 24, 2022

The recall does not pertain to the interchangeable biosimilars, Semglee (insulin glargine-yfgn) injection, or Insulin Glargine (insulin glargine-yfgn) injection.

Next post in Diabetes